Welireg Approved for Advanced Renal Cell Carcinoma
The FDA has approved Welireg (belzutifan) to treat adults with advanced RCC who previously received a PD-1/L1 inhibitor and a VEGF TKI.
Source: cancertherapyadvisor.com
📰 Boxed Warning News
Page 11 - Boxed Warning News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Boxed Warning. Real-time updates on events, politics, business and more.
Welireg Approved for Advanced Renal Cell Carcinoma
The FDA has approved Welireg (belzutifan) for the treatment of adult patients with advanced RCC following a PD-1 or PD-L1 inhibitor and a VEGF-TKI.
Source: empr.com
ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is
ZURZUVAE, the first and only oral, once-daily, 14-day treatment course, has shown to provide rapid improvements in depressive symptoms at Day 15 and as early as Day 3 for women with PPDPatient support program, ZURZUVAE For You, and financial assistance available to eligible women with PPD prescribed ZURZUVAEPatients...
Source: pharmiweb.com
Oral Postpartum Depression Treatment Zurzuvae Now Available
Zurzuvae™ (zuranolone) is now available for the treatment of postpartum depression in adults.
New York United States Kristina Deligiannidis Chris Benecchi Feinstein Institutes For Medical Research In Manhasset Feinstein Institutes
Source: empr.com
New Analyses Demonstrate Versatility and Continued Efficacy of TALVEY™ in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
/PRNewswire/ -- Johnson & Johnson announced today an analysis from the Phase 1/2 MonumenTAL-1 study of TALVEY™ (talquetamab-tgvs) in patients with relapsed or...
United States San Francisco Christie Corbett Satu Glawe Christoph Heuck American Society Of Hematology
Source: prnewswire.com
Patient-Reported Outcomes from the CARTITUDE-4 Study Showed Clinically Meaningful Improvements in Health-Related Quality of Life and Reductions in Multiple Myeloma Symptoms Following Treatment with CARVYKTI® (ciltacabtagene autoleucel)
SOMERSET, N.J.--(BUSINESS WIRE)--Dec 11, 2023--
Source: eagletribune.com
Patient-Reported Outcomes from the CARTITUDE-4 Study Showed Clinically Meaningful Improvements in He
In CARTITUDE-4, CARVYKTI® demonstrated clinically meaningful improvements in patient-reported outcomes when compared to standard of careThe as-treated population in CARTITUDE-4 demonstrated strong rates of progression-free survival and overall responseLonger-term data from CARTITUDE-2 showed deep and durable respons...
Source: pharmiweb.com
Axsome Therapeutics Presents New Data and Post-Hoc Analyses of Auvelity® in Patients with Major ...
New data on Auvelity’s impact on quality of life, measured by the Q-LES-Q-SF, in patients who had received at least one prior treatment during their current depressive episode
Source: eagletribune.com
Bluebird bio Announces FDA Approval of LYFGENIA™ (lovotibeglogene autotemcel) for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events
Severe vaso-occlusive events were eliminated for 94% of evaluable patients and all VOEs were eliminated for 88% of evaluable patients between 6 and 18 months post-infusion LYFGENIA is the most...
United States Andrew Obenshain John Tisdale Regina Hartfield Julie Kanter Sickle Cell Disease Association Of America Inc
Source: marketscreener.com
Bluebird bio Details Plans for the Commercial Launch of LYFGENIA™ Gene Therapy for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events
Outcomes-based contract offerings available to both commercial payers and Medicaid LYFGENIA will be available through bluebird’s established national network of Qualified Treatment Centers...
United States Tom Klima Shantel Herbert Magee Exchange Commission Treatment Centers Qtcs Treatment Centers
Source: marketscreener.com